Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 3/20 | 0.47 |
| ▸ | CA7 | P43166 | 3/20 | 0.47 |
| ▸ | CA9 | Q16790 | 3/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1508826 | 1.00 | ATM (0.56) | ATMMEN1KMT2AL3MBTL1MAPT | |
| SCHEMBL7907847 | 1.00 | ATM (0.56) | ATMMEN1KMT2AL3MBTL1MAPT | |
| SCHEMBL28941574 | 0.90 | ALDH1A1 (0.56) | ATMMEN1KMT2AL3MBTL1MAPT | |
| SCHEMBL13936584 | 0.87 | ALDH1A1 (0.50) | MEN1KMT2AL3MBTL1POLBTRPM8 | |
| SCHEMBL12406830 | 0.87 | ALDH1A1 (0.50) | MEN1KMT2AL3MBTL1POLBTRPM8 | |
| SCHEMBL3959739 | 0.87 | ATM (0.68) | ATMMEN1KMT2AL3MBTL1POLB | |
| SCHEMBL2375644 | 0.87 | ATM (0.68) | ATMMEN1KMT2AL3MBTL1POLB | |
| SCHEMBL14636601 | 0.87 | ATM (0.56) | ATMMEN1KMT2AL3MBTL1MAPT | |
| SCHEMBL304265 | 0.87 | ATM (0.56) | ATMMEN1KMT2AL3MBTL1MAPT | |
| SCHEMBL5878196 | 0.87 | ATM (0.56) | ATMMEN1KMT2AL3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125378-A2 | Heterocyclic Compounds | BEONE MEDICINES I GMBH (CH) | 2026-05-07 | — | — | US | disclosed |
| US-20260008787-A1 | FUSED RING KRAS INHIBITORS FOR TREATING DISEASE | BLOSSOMHILL THERAPEUTICS INC (US) | 2026-01-08 | — | — | US | disclosed |
| US-20250353846-A1 | Heterocyclic Compounds | BEONE MEDICINES I GMBH (CH) | 2025-11-20 | — | — | US | disclosed |
| EP-4021901-B1 | SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2025-09-24 | — | — | EP | disclosed |
| EP-4551577-A1 | FUSED RING KRAS INHIBITORS FOR TREATING DISEASE | Blossomhill Therapeutics, Inc. (US) | 2025-05-14 | — | — | EP | disclosed |
| US-20240400563-A1 | SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL-MYERS SQUIBB COMPANY | 2024-12-05 | — | — | US | disclosed |
| US-12024509-B2 | Therapeutic compounds as inhibitors of the orexin-1 receptor | C4X DISCOVERY LIMITED (GB) | 2024-07-02 | — | — | US | disclosed |
| US-12024509-B2 | Therapeutic compounds as inhibitors of the orexin-1 receptor | C4X DISCOVERY LIMITED (GB) | 2024-07-02 | — | — | US | disclosed |
| US-12024509-B2 | Therapeutic compounds as inhibitors of the orexin-1 receptor | C4X DISCOVERY LIMITED (GB) | 2024-07-02 | — | — | US | disclosed |
| CN-114302884-B | Substituted pyridopyrimidinone compounds useful as T cell activators | 百时美施贵宝公司 | 2024-06-04 | — | — | CN | disclosed |
| WO-2016034882-A1 | THERAPEUTIC COMPOUNDS AS INHIBITORS OF THE OREXIN-1 RECEPTOR | C4X DISCOVERY LIMITED (GB) | 2016-03-10 | — | — | WO | disclosed |
| US-9175038-B2 | Peptide mimetic ligands of polo-like kinase 1 polo box domain and methods of use | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2015-11-03 | — | — | US | disclosed |
| US-20140142044-A1 | PEPTIDE MIMETIC LIGANDS OF POLO-LIKE KINASE 1 POLO BOX DOMAIN AND METHODS OF USE | The United States of America, as represented by the Secretary, Department of Health & Human Servic (US) | 2014-05-22 | — | — | US | disclosed |
| US-20130172362-A1 | Imidazothiazole Derivatives Having Proline Ring Structure | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-07-04 | — | — | US | disclosed |
| US-20130172362-A1 | Imidazothiazole Derivatives Having Proline Ring Structure | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-07-04 | — | — | US | disclosed |
| US-8404691-B2 | Imidazothiazole derivatives having proline ring structure | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-03-26 | — | — | US | disclosed |
| US-8404691-B2 | Imidazothiazole derivatives having proline ring structure | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-03-26 | — | — | US | disclosed |
| US-20120065146-A1 | PEPTIDE MIMETIC LIGANDS OF POLO-LIKE KINASE 1 POLO BOX DOMAIN AND METHODS OF USE | GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH (US) | 2012-03-15 | — | — | US | disclosed |
| EP-2380892-A1 | IMIDAZOTHIAZOLE DERIVATIVE HAVING PROLINE RING STRUCTURE | Daiichi Sankyo Company, Limited (JP) | 2011-10-26 | — | — | EP | disclosed |
| EP-2298778-A1 | IMIDAZOTHIAZOLE DERIVATIVE HAVING 4,7-DIAZASPIROÝ2.5¨OCTANE RING STRUCTURE | Daiichi Sankyo Company, Limited (JP) | 2011-03-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125378-A2 | Heterocyclic Compounds | NFATC1, CD4, MALT1 | ATM 3845/4885MEN1 3179/4885KMT2A 3652/4885 |
| US-20240400563-A1 | SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | DGKZ, DGKA, DGKG | ATM 1297/4885MEN1 2784/4885KMT2A 2162/4885 |
| US-20130172362-A1 | Imidazothiazole Derivatives Having Proline Ring Structure | MDM2, TP53, TP53BP1 | ATM 1063/4885MEN1 3904/4885KMT2A 1912/4885 |
| US-20140142044-A1 | PEPTIDE MIMETIC LIGANDS OF POLO-LIKE KINASE 1 POLO BOX DOMAIN AND METHODS OF USE | PLK1, PLK4, PLK3 | ATM 1538/4885MEN1 4339/4885KMT2A 2194/4885 |
| US-20120065146-A1 | PEPTIDE MIMETIC LIGANDS OF POLO-LIKE KINASE 1 POLO BOX DOMAIN AND METHODS OF USE | PLK1, PLK2, PLK4 | ATM 387/4885MEN1 2031/4885KMT2A 2980/4885 |
| US-12024509-B2 | Therapeutic compounds as inhibitors of the orexin-1 receptor | HCRTR1, HCRTR2, NPY1R | ATM 4817/4885MEN1 649/4885KMT2A 2362/4885 |
| US-20250353846-A1 | Heterocyclic Compounds | NFATC1, CD4, ACIN1 | ATM 1155/4885MEN1 3612/4885KMT2A 2438/4885 |
| US-20260008787-A1 | FUSED RING KRAS INHIBITORS FOR TREATING DISEASE | KRAS, NRAS, HRAS | ATM 1382/4885MEN1 3131/4885KMT2A 2867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.